STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, tackle a pair of related topics: what the STEP HFpEF DM trial from ACC.24 means for the diabetes community and the need for fair and equitable allocation of incretin-based therapies in the face of ongoing drug shortages and overwhelming demand.

Episode metadata supplied by the publisher feed · Published Apr 20, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

0:00 23:31

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 23 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on April 20, 2024.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!